News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sofregen Medical Bolsters Leadership Team And Board



11/10/2016 2:12:09 PM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

Company Brings On Industry Veterans Chris White and Doug Shelton to Move Silk-Based Products Platform Forward

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sofregen Medical Inc. today announced major additions to its leadership team and Board of Directors. The company named Chris White as President and Chief Operating Officer and Doug Shelton as an independent director of the company. Both industry veterans join a team that is committed to bringing a novel pipeline of natural, silk-based products to the aesthetics and reconstructive surgery markets.

“Both senior management and our Board of Directors have the experience and skill set to deliver on our commitment to treat both disfiguring injuries and delicate soft tissue defects in the most effective manner possible.”

In his new role, Chris White will be responsible for the internal development and commercialization of the Sofregen product pipeline as well as acquisitions of strategically aligned medical technologies. White brings 25 years of product, operations management, sales, marketing and business development experience in the biopharmaceutical industry. Prior to joining Sofregen, he was the Chief Business Officer at Entasis Therapeutics and AMAG Pharmaceuticals. He will report directly to Howard Weisman, Chairman of the Board.

White joins a leadership team that brings with it a unique skill set of both science and business acumen. Anh Hoang, Ph.D., Chief Science Officer, directs the activities of the scientific team working to advance the company’s product portfolio. Dr. Hoang has published in high impact peer-reviewed journals on medical devices and has considerable experience in biomaterial research. Milan Kofol, CPA, Chief Financial Officer, is responsible for Sofregen’s finance and accounting activities. Kofol also oversees Human Resources and Information Technology. He previously served as Vice President, Treasurer and Investor Relations at Boston Scientific Corporation.

Board of Directors

Sofregen also announced the appointment of Doug Sheldon as an independent director of the company. Sheldon is an accomplished entrepreneur and pharmaceutical executive with over 30 years of global experience. He is currently Executive Chairman at Indochina Healthcare Ltd., a Bangkok-based, specialty pharma and medical device company which he founded in 1994. He is also co-founder of ESP Pharma and EKR Therapeutics, specialty pharma companies focused on the hospital critical care market. He is Managing Partner of ESP Equity Partners LLC. His previous experience includes senior level executive positions at Warner Lambert, Parke Davis and Pfizer.

Sofregen’s Chairman Howard Weisman shared his enthusiasm for the contributions he anticipates to be made by both individuals and his senior team:

“We have a promising and innovative product platform that will be moved decidedly forward by this outstanding leadership team,” said Weisman. “Both senior management and our Board of Directors have the experience and skill set to deliver on our commitment to treat both disfiguring injuries and delicate soft tissue defects in the most effective manner possible.”

About Sofregen Medical Inc.

Founded in 2014 to advance technology developed at Tufts University, Sofregen is a pioneer in the use of silk, nature’s healing fiber, in a variety of forms to help physicians address soft tissue defects, giving patients a fresh start, restoring confidence, and improving quality of life. Sofregen is committed to restoring function and cosmetic appearance for medical and aesthetic patients worldwide. For more information, please visit www.sofregenmedical.com.

Contacts

For Sofregen Medical
Emily Mendell, 781-522-6732
emendell@polarispartners.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES